EMAIL THIS PAGE TO A FRIEND

Biological & pharmaceutical bulletin

Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.


PMID 25366478

Abstract

Delamanid is a new drug for the treatment of multidrug-resistant tuberculosis. Individuals who are co-infected with human immunodeficiency virus and Mycobacterium tuberculosis may require treatment with a number of medications that might interact significantly with the CYP enzyme system as inhibitors or inducers. It is therefore important to understand how drugs in development for the treatment of tuberculosis will affect CYP enzyme metabolism. The ability of delamanid to inhibit or induce CYP enzymes was investigated in vitro using human liver microsomes or human hepatocytes. Delamanid (100 µM) had little potential for mechanism-based inactivation on eight CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). Delamanid's metabolites were noted to inhibit the metabolism of some CYP isoforms, but these effects were observed only at metabolite concentrations that were well above those observed in human plasma during clinical trials. Delamanid (≤10 µM) did not induce CYP1A2, CYP2C9, and CYP3A4 activities in human hepatocytes, and there were no increases in CYP1A2, CYP2B6, CYP2C9, and CYP3A4 mRNA levels. Taken together, these data suggest that delamanid is unlikely to cause clinically relevant drug-drug interactions when co-administered with products that are metabolized by the CYP enzyme system.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

UC148
6-Hydroxychlorzoxazone, ≥98% (HPLC)
C7H4ClNO3
C188
6-Hydroxychlorzoxazone, solid
C7H4ClNO3
B102
Bupropion hydrochloride, ≥98% (HPLC), solid
C13H18ClNO · HCl
1078733
Bupropion hydrochloride, United States Pharmacopeia (USP) Reference Standard
C13H18ClNO · HCl
C4397
Chlorzoxazone
C7H4ClNO2
Y0001635
Diclofenac for system suitability, European Pharmacopoeia (EP) Reference Standard
C14H10Cl2NNaO2
S0765000
Diclofenac sodium, European Pharmacopoeia (EP) Reference Standard
C14H10Cl2NNaO2
1188800
Diclofenac sodium, United States Pharmacopeia (USP) Reference Standard
C14H10Cl2NNaO2
D6899
Diclofenac sodium salt
C14H10Cl2NNaO2
93484
Diclofenac sodium salt, analytical standard
C14H10Cl2NNaO2
PHR1144
Diclofenac sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material
C14H10Cl2NNaO2
N114
Nifedipine
C17H18N2O6
N0750000
Nifedipine, European Pharmacopoeia (EP) Reference Standard
C17H18N2O6
1463508
Nifedipine, United States Pharmacopeia (USP) Reference Standard
C17H18N2O6
PHR1290
Nifedipine, Pharmaceutical Secondary Standard; Certified Reference Material
C17H18N2O6
N0750010
Nifedipine impurity A, European Pharmacopoeia (EP) Reference Standard
C17H16N2O6
1463600
Nifedipine Nitrophenylpyridine Analog, United States Pharmacopeia (USP) Reference Standard
C17H16N2O6
UC167
Oxidized Nifedipine, powder, ~95% (HPLC)
C17H16N2O6
77440
Phenacetin, ≥98.0% (HPLC)
C10H13NO2
PHR1249
Phenacetin
C10H13NO2
PHR1094
Phenacetin melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
C10H13NO2
1514008
Phenacetin Melting Point Standard, United States Pharmacopeia (USP) Reference Standard
C10H13NO2
424455
Resorufin, Dye content 95 %
C12H7NO3
73144
Resorufin, 95%
C12H7NO3
T0891
Tolbutamide, analytical standard
C12H18N2O3S
46968
Tolbutamide, VETRANAL, analytical standard
C12H18N2O3S
T1700000
Tolbutamide, European Pharmacopoeia (EP) Reference Standard
C12H18N2O3S
93979
Umbelliferone, suitable for fluorescence indicator, ≥98.0% (HPLC)
C9H6O3
H24003
Umbelliferone, 99%
C9H6O3
54826
Umbelliferone, analytical standard
C9H6O3